HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors. (2024)
Attributed to:
Understanding and targeting oncogenic biomolecular condensates of ALK kinase
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.21037/tlcr-23-804
PubMed Identifier: 38496685
Publication URI: http://europepmc.org/abstract/MED/38496685
Type: Journal Article/Review
Volume: 13
Parent Publication: Translational lung cancer research
Issue: 2
ISSN: 2218-6751